MINOCIN Drug Patent Profile
✉ Email this page to a colleague
When do Minocin patents expire, and what generic alternatives are available?
Minocin is a drug marketed by Bausch, Triax Pharms, Lederle, and Rempex. and is included in five NDAs. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has thirty patent family members in twenty-two countries.
The generic ingredient in MINOCIN is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Minocin
A generic version of MINOCIN was approved as minocycline hydrochloride by WATSON LABS on December 30th, 1991.
Summary for MINOCIN
| International Patents: | 30 |
| US Patents: | 2 |
| Applicants: | 4 |
| NDAs: | 5 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 129 |
| Clinical Trials: | 44 |
| Patent Applications: | 3,250 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for MINOCIN |
| What excipients (inactive ingredients) are in MINOCIN? | MINOCIN excipients list |
| DailyMed Link: | MINOCIN at DailyMed |
Recent Clinical Trials for MINOCIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Baystate Medical Center | Phase 2 |
| Children's Hospital Medical Center, Cincinnati | Phase 1 |
| Sun Yat-sen University | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for MINOCIN
Paragraph IV (Patent) Challenges for MINOCIN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MINOCIN | Injection | minocycline hydrochloride | 100 mg/vial | 050444 | 1 | 2020-10-16 |
US Patents and Regulatory Information for MINOCIN
MINOCIN is protected by two US patents.
Patents protecting MINOCIN
Tetracycline compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS
Tetracycline compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | MINOCIN | minocycline hydrochloride | CAPSULE;ORAL | 050649-001 | May 31, 1990 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| Rempex | MINOCIN | minocycline hydrochloride | INJECTABLE;INJECTION | 050444-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Triax Pharms | MINOCIN | minocycline hydrochloride | CAPSULE;ORAL | 050315-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Rempex | MINOCIN | minocycline hydrochloride | INJECTABLE;INJECTION | 050444-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MINOCIN
See the table below for patents covering MINOCIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2013529201 | See Plans and Pricing | |
| Portugal | 2568987 | See Plans and Pricing | |
| Japan | 2016145253 | テトラサイクリン組成物 (TETRACYCLINE COMPOSITIONS) | See Plans and Pricing |
| Mexico | 347919 | COMPOSICIONES DE TETRACICLINA. (TETRACYCLINE COMPOSITIONS.) | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
